Harvard Bioscience (HBIO) Tops Q4 EPS by 1c

Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.06, $0.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $24.6 million versus the consensus estimate of $24.15 million.

GUIDANCE:

Harvard Bioscience sees Q1 2025 revenue of $19-21 million.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
• First Horizon National (FHN) Tops Q2 EPS by 2c
• PNC Financial Services (PNC) Tops Q2 EPS by 38c, Beats on Revenue